5AM Ventures, the life sciences venture fund with offices in Waltham, MA and Menlo Park, CA, has raised a $200 million for a new fund, according to a statement. Most of the fund will go early-stage investments to develop new drugs, although it will put “a meaningful portion” of the fund into diagnostics, materials, medical devices, and reagents. The venture firm, founded in 2002, has made 27 investments in early stage life sciences companies.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
